Sarepta CEO Doug Ingram buys $2M batch of his biotech's stock; Express Scripts exploring exclusive gene therapy deals
→ Sarepta’s shares $SRPT have climbed fast since Doug Ingram stepped in as CEO and had a chance to do some deals and reap the benefits of a promising early-stage gene therapy program. As we’ve noted before, Ingram has a rich pay package tied to the performance of the company’s stock. And he’s demonstrating some personal confidence by adding $2 million worth of shares in the biotech to his portfolio. The stock purchase was outlined in an SEC filing, which has had some prominent distribution this morning on Twitter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.